Wilson’s disease—cause of mortality in 164 patients during 1992–2003 observation period

Berman J (1988) Cell proliferation and the etiology of hepatocellular carcinoma. J Hepatol 7:305–309

Brewer GJ, Terry CA, Aisen AM, Hill GM (1987) Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 44:490–493

Brewer GJ, Yusbasiyan-Gurkan V, Tankanow R (1991) Initial therapy of Wilson’s patients with tetrathiomolybdate. Arch Neurol 48:42–47

Cheng W, Govindarajan S, Redeker A (1992) Hepatocellular carcinoma in a case ofWilson’s disease. Liver 12:43–45

Członkowska A, Galewicz A, Rodo M, Wehr H (1973) Observation on copper metabolism in Wilson’s disease. Acta Univ Caro Med 56:175–178

Członkowska A, Milewski B (1976) Immunological observations on patients with Wilson’s disease. J Neurol Sci 29:411–421

Członkowska A (1977) The influence of prolonged treatment with d-penicillamine on the immune response in Wilson’s disease. Europ J Clin Pharmacol 12:265–271

Członkowska A, Gajda J, Rodo M (1996) Effects of long-term treatment in Wilson’s disease with d-penicillamine and zinc sulphate. J Neurol 243:269–273

Gibbs K, Walshe JM (1990) Liver copper concentration in Wilson’s disease: effect of treatment with anti-copper agents. J Gastroent Hepatol 5:420–424

Gross J, Balan V, Scolapio J (1995) Survival in treated patients with Wilson’s disease: long-term follow up in 127 patients. Zeitschrift fur Gastroenterologie 33:485

Hakulinen T, Abewickrama K (1985) A computer program package for relative survival analysis; Computer Programs in Biomedicine 19:197–207

Hoogenraad T (1997) Wilson’s Disease. London, Philadelphia, Toronto, Sydney, Tokyo: W. B. Saunders Company Ltd., pp 14–24, 72–73

Polio J, Enriquez R, Chow A, Wood W, Atterbury C (1989) Hepatocellular carcinoma in Wilson’s disease. Case report and review of literature. J Clin Gastroenterol 11:220–224

Robertson WM (2000) Wilson’s disease. Arch Neurol 57:276–277

Scheinberg I, Jaffe M, Sternlieb I (1987) The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson’s disease. N Eng J Med 317:209–213

Schiefermeier M, Kolleger H, Madl C, Polli C, Oder W, Kuhn H, Berr F, Ferenci P (2000) The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson’s disease. Brain 123:585–590

Schilsky ML, Scheinberg H, Sternlieb I (1991) Prognosis of Wilsonian Chronic Active Hepatitis. Gastroenterology 100:762–767

Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW (1995) The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 9:210–217

Walshe JM (1956) Penicillamine a new oral therapy for Wilson’s disease. Am J Med 21:487–495

Walshe JM (1982) Treatment ofWilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1:643–647

Walshe JM (1988) Wilson’s disease: yesterday, today, and tomorrow. Mov Disord 3:10–29

Wilkinson M, Portmann B, Williams R (1983) Wilson’s disease and the hepatocellular carcinoma: possible role of copper. Gut 24:767–771

Yusbasiyan-Gurkan V, Grider A, Nostrant T (1992) The treatment ofWilson’s disease with zinc: intestinal metallothionein induction. J Lab Clin Med 120:380–386